中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 32 Issue 1
Jan.  2016
Turn off MathJax
Article Contents

Effect of recombinant human endostatin combined with hepatic artery interventional therapy on progression-free survival of patients with advanced hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2016.01.016
  • Received Date: 2015-10-19
  • Published Date: 2016-01-20
  • Objective To investigate the effect of recombinant human endostatin( Endostar) combined with hepatic artery interventional therapy on the progression- free survival( PFS) of patients with advanced hepatocellular carcinoma( HCC). Methods A total of 86 patients with advanced HCC who were admitted to Fujian Provincial Tumor Hospital from March 2011 to May 2015 were selected and divided into treatment group and control group according to a matched pair design. The treatment group( 43 patients) was given Endostar combined with hepatic artery interventional therapy,and the control group( 43 patients) was given hepatic artery interventional therapy combined with oral administration of Ganfule. The chi- square test was applied for comparison of categorical data between the two groups,and the t- test was applied for comparison of continuous data between the two groups. The Kaplan- Meier method was applied for survival analysis,the Log- rank test was applied for univariate analysis,and Cox proportional hazards model was applied for multivariate analysis. Results The median PFS in the treatment group and the control group was 154 d [95% confidence interval( CI) : 94- 214 d]and 70 d( 95% CI: 39- 101d),respectively,with a significant difference between the two groups( χ2= 10. 741,P = 0. 001). Univariate analysis showed that the severity of liver cirrhosis,number of tumors,and main portal vein tumor thrombus / inferior vena cava tumor thrombus were the prognostic factors for patients with advanced HCC( χ2= 8. 182,9. 150,and 6. 565,P = 0. 004,0. 027,and 0. 038); multivariate analysis showed that the severity of liver cirrhosis and main portal vein tumor thrombus / inferior vena cava tumor thrombus were the independent prognostic factors for PFS in patients with advanced HCC who were treated with Endostar combined with hepatic artery interventional therapy( P = 0. 028 and 0.013). Conclusion Endostar can effectively prolong the PFS of patients with advanced HCC after hepatic artery interventional therapy,but it does not have a clear advantage in patients with severe liver cirrhosis or main portal vein tumor thrombus / inferior vena cava tumor thrombus.

     

  • loading
  • [1]YE SL,QIN SK,WU MC,et al.Consensus on standardized diagnosis and treatment of primary liver cancer[J].J Clin Hepatol,2009,25(2):83-92.(in Chinese)叶胜龙,秦叔逵,吴孟超,等.原发性肝癌规范化诊治的专家共识[J].临床肝胆病杂志,2009,25(2):83-92.
    [2]DIGTYAR AV,POZDNYAKOVA NV,FELDMAN NB,et al.Endostatin:current concepts about its biological role and mechanisms of action[J].Biochemistry(Mosc),2007,72(3):235-246.
    [3]HUANG X,WONG MK,ZHAO Q,et al.Soluble recombinant endostatin purified from Escherichia coli:antiangiogenic activity and antitumor effect[J].Cancer Res,2001,61(2):478-481.
    [4]LI B,WU XY,ZHOU H,et al.Acid-induced unfolding mechanism of recombinant human endostatin[J].Biochemistry,2004,43(9):2550-2557.
    [5]Ministry of Health of the People's Republic of China.Diagnosis,management,and treatment of hepatocellular carcinoma(V2011)[J].J Clin Hepatol,2011,27(11):1141-1159.(in Chinese)中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.
    [6] HAO MZ,LIN HL,CHEN QZ,et al.Efficacy of transcatheter arterial infusion alone or combined with transcatheter arterial chemoembolization on advanced hepatocellular carcinoma with portal vein tumor thrombus in the main trunk[J/OL].Contemp Interv Med,2015,1(3).http://www.intervmed.com/2015010316.html.(in Chinese)郝明志,林海澜,陈起忠,等.合并门脉主干癌栓的晚期肝癌肝动脉介入治疗的疗效观察[J/OL].当代介入医学,2015,1(3).http://www.intervmed.com/2015010316.html.
    [7]LENCIONI R,LLOVET JM.Modified RECIST(mRECIST)assessment for hepatocellular carcinoma[J].Semin Liver Dis,2010,30(1):52-60.
    [8]WEI Y,TU R,CHEN ZM,et al.Hepatic functional reserve and prognosis after liver interventional therapy:evaluation by CT grading of liver cirrhosis[J].J Clin Radiol,2010,29(12):1671-1674.(in Chinese)韦勇,涂蓉,陈忠明,等.肝硬化CT分级评估肝癌介入治疗肝储备功能及预后研究[J].临床放射学杂志,2010,29(12):1671-1674.
    [9]LLOVET JM,BRUIX J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:chemoembolization improves survival[J].Hepatology,2003,37(2):429-442.
    [10]LO CM,NGAN H,TSO WK,et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology,2002,35(5):1164-1171.
    [11]MARUYAMA K,OCHIAI A,AKIMOTO S,et al.Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer[J].Oncology,2000,59(4):302-309.
    [12]ANDO E,TANAKA M,YAMASHITA F,et al.Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis:analysis of 48 cases[J].Cancer,2002,95(3):588-595.
    [13]KUDO M,MATSUI O,IZUMI N,et al.JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma:2014 update by the liver cancer study group of Japan[J].Liver Cancer,2014,3(3-4):458-468.
    [14]FOLKMAN J.Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J].Exp Cell Res,2006,312(5):594-607.
    [15]WANG JW,SUN Y,LIU YY,et al.Results of randomized,multicenter,double-blind phaseⅢtrial of rh-endostatin(YH-16)in treatment of advanced non-small cell lung cancer patients[J].Chin J Lung Cancer,2005,8(4):283-290.(in Chinese)王金万,孙燕,刘永煜,等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290.
    [16]LIU XF,QIN SK,WANG L,et al.Endostar combined with chemotherapy on the multiple kinds of advanced malignancies[J].Chin Clin Oncol,2007,12(4):241-245.(in Chinese)刘秀峰,秦叔逵,王琳,等.恩度与化疗联合治疗多种晚期恶性肿瘤的临床观察[J].临床肿瘤学杂志,2007,12(4):241-245.
    [17]REN TJ,SHAN FX,HOU JF,et al.Efficacy and safety of combined XELOX and Endostar therapy as first-line treatment for patients with advanced biliary tract carcinoma[J].Chin J Oncol Prev Treat,2015,7(1):41-44.(in Chinese)任铁军,单风晓,侯建峰,等.XELOX方案联合恩度一线治疗晚期胆系肿瘤的临床观察[J].中国癌症防治杂志,2015,7(1):41-44.
    [18]WANG YZ.Endostar infusion combined with interventional chemotherapy and embolization interventional therapy in treatment of advanced liver cancer[J].Modern Prevent Med,2011,38(2):399-341.(in Chinese)王永中.恩度静脉滴注联合介入化疗栓塞治疗中晚期肝癌的临床研究[J].现代预防医学,2011,38(2):399-341.
    [19]HAO MZ,CHEN WJ,LIN HL,et al.Efficacy of transcatheter arterial chemoembolization combined with Ganfule capsules on advanced hepatocellular carcinoma[J].Central South Pharm,2013,11(2):147-150.(in Chinese)郝明志,陈武进,林海澜,等.肝动脉栓塞化疗联合肝复乐胶囊治疗晚期肝癌临床疗效观察[J].中南药学,2013,11(2):147-150.
    [20]JEONG SW,JANG JY,SHIM KY,et al.Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis[J].Gut Liver,2013,7(6):696-703.
    [21]ZHANG Y,FAN W,WANG Y,et al.Sorafenib with and without transarterial chemoembolization for advanced hepatocellular carcinoma with main portal vein tumor thrombosis:a retrospective analysis[J].Oncologist,2015,20(12):1417-1424.
    [22]MENG ZQ,LIU LM,MA X,et al.Prognosis risk factors and therapeutic effect analysis in primary hepatic carcinoma:394 cases report[J].China Oncol,2007,17(8):628-632.(in Chinese)孟志强,刘鲁明,马鑫,等.394例原发性肝癌的预后因素与疗效分析[J].中国癌症杂志,2007,17(8):628-632.
    [23]JIA QL,GAO WQ.Prognostic factors affecting TACE treatment in patients with primary hepatic carcinoma[J].J Henan Univ Sci Tech:Med Sci,2009,27(2):158-160.(in Chinese)贾群玲,高万勤.影响原发性肝癌病人TACE治疗的预后因素[J].河南科技大学学报:医学版,2009,27(2):158-160.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2482) PDF downloads(421) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return